Accreditation

This Group Learning program has been reviewed by the College of Family Physicians of Canada and certified for 6 Mainpro+ credits per 2-hour session. For physicians to receive the full credits, the post-session practice reflection survey must be completed 6 weeks after the session.

Note: Final certification is granted upon ethical review and approval of the session application
that must be submitted at least 10 days in advance of the session date.

All content is developed independently with a scientific committee to ensure the integrity of the programs to the best practices outlined in the 2022 Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care. 

​

Modules are theory informed and based on adult education and learning principles. 

Learn more about the Theory and Adult Education Principles for CHEP+ Programs

​​

​

MODULE TOPICS

​

ENGLISH MODULES 

 

CV Risk Reduction in Diabetes (Newly Updated 2025)

The overall objectives for participants of the program are to:

• Describe the patient who should be treated with an SGLT2i/GLP-1 agonist/nsMRA

• Explain the rationale for this treatment and the potential benefits

• Describe the steps for initiating and monitoring therapy for patients with diabetes

 

Management of Patients with Diabetes and Hypertension  1 (Newly Updated 2025)

Upon completion of this activity, participants should be able to:

• Formulate a multifaceted approach to reduce CV and Kidney risk. 

• Formulate a treatment plan to achieve blood pressure control for patients with diabetes and hypertension using the latest C-CHANGE Canadian Harmonized clinical practice guidelines.

• Assess the specific need in patients with diabetes for the use of RAAS blockers, SGLT2i, nsMRA, GLP1-RA and antihyperglycemic agents with demonstrated CV and/or kidney benefit to reduce cardiovascular and renal events

 

Management of Patients with Diabetes and Hypertension 2

Upon completion of this case study, participants should be able to:

• Plan the investigation of patients with hypertension and diabetes including evaluation for nephropathy

• Assess the risk associated with diabetes in patients with hypertension including the impact of diabetic nephropathy

• Demonstrate knowledge of the blood pressure target in patients with hypertension living with diabetes

 

Demonstrate knowledge of the blood pressure target in people with hypertension living with diabetes

The overall objectives for participants of the program are to:

• Plan the investigation of patients with hypertension and diabetes, including evaluation for nephropathy

• Select treatment for patients with hypertension and diabetes with or without nephropathy

• Assess and manage vascular and modifiable risk factors

 

CHF and Hypertension: Management of Hypertension to Prevent Heart Failure and Atrial Fibrillation

The overall objectives for participants of the program are to:

• Apply the Hypertension Canada clinical practice guidelines for the management of hypertension in association with heart failure

• Explain the relationship between hypertension and heart failure, and in relation to a specific case

• Explain the relationship between hypertension and atrial fibrillation, and in relation to a specific case 

​

Hypertension and Single Pill Combination Therapy

• Review the new Hypertension Canada recommendations for the use of single pill combinations in the treatment of hypertension

• Outline the rationale and background evidence for using single pill combination therapy as initial and ongoing therapy in the treatment of hypertension

• Describe a method for introducing a single pill combination as the initial treatment of hypertension to maximize effectiveness and minimize side effects

 

Management of Hypertension in Non-diabetes Patients with Chronic Kidney Disease

Upon completion of this activity, participants will be able to:

• State the new BP target for patients with non-DM CKD and understand the rationale for this change

• Identify the risk of developing CKD from HTN is graded based on race and comorbidities

• Understand and manage the increases in risk for cardiovascular outcomes in patients with non-DM CKD and hypertension

 

Management of Hypertension in Patients with Chronic Kidney Disease

Upon completion of this activity, participants should be able to:

• Identify a patient with chronic kidney disease.

• Formulate a treatment plan for cardiovascular risk reduction using the C-CHANGE guidelines including BP control and lipid management and SGLT2i. 

• Communicate and initiate the treatment plan to reduce cardiovascular risk in patients with chronic kidney disease

 

Blood Pressure Management: Diagnosis, Treatment and Follow Up

Upon completion of this case study, participants should be able to:

• To describe the new Hypertension Canada recommendations and algorithm for the diagnosis of hypertension

• To outline the rationale for and the methods for using automated office blood pressure measurements.

• Define White Coat Hypertension, Masked Hypertension, and Masked Uncontrolled Hypertension (MUCH)

• To describe tools for helping learners acquire and teach the knowledge and skills for blood pressure measurement.

 

Hypertension, Lifestyle and Sodium

Upon completion of this case study, participants should be able to:

• Apply the Hypertension Canada recommendations for the management of hypertension in association with sodium and lifestyle

• Explain the relationship between hypertension and sodium, how to prevent and manage hypertension with lifestyle modifications, and a multi-pronged approach

• Recognize high sodium content food items and lower sodium options

 

How C-CHANGE can help clinicians manage the multi co-morbidity patient

Upon completion of this activity, participants will be able to:

• Identify recommendations for multiple morbidities from the C-CHANGE guidelines

• Implement recommendations for multiple morbidities in a single patient

• Use the C-CHANGE recommendations to help keep the elderly living at home longer and healthier

 

Hypertension and Stroke Prevention and Management in Patients

Upon completion of this case study, participants should be able to:

• Plan to assess and screen patients blood pressure at all appropriate visits.

• Discuss modifiable cardiovascular risk factors with patients.

• Discuss blood pressure targets and need for anticoagulation/anti-platelet therapy in people who have just suffered a stroke.

 

Global Cardiovascular Risk Assessment and Reduction in Women

Upon completion of this activity, participants should be able to:

• Identify recommendations for multiple comorbidities from the C-CHANGE guidelines

• Implement recommendations for multiple comorbidities in a single patient

• Use the C-CHANGE recommendations to help manage female patients with multiple CV risk factors

 

Global Cardiovascular Risk Assessment and Risk Reduction Women with Hypertension

Upon completion of this activity, participants should be able to:

• Do a critical appraisal of CV risk assessment

• Evaluate indications and limitations of CV risk stratification

• Calculate vascular age; discuss how vascular age assessment can help in CV risk reduction

• Formulate a management plan using the Hypertension Canada recommendations

 

Anticoagulation in Nonvalvular Atrial Fibrillation in Patients with Renal Disease

• Describe the rational for anticoagulation of non-valvular atrial fibrillation

• Describe the effect on outcomes of non-valvular atrial fibrillation with CKD

• Describe the management of patients with CKD and non-valvular atrial fibrillation

 

ARNI in Reduced Ejection Fraction Heart Failure (HFrEF)

• Describe the epidemiology and pathophysiology of reduced ejection fraction heart failure (HFrEF) and preserved ejection fraction heart failure (HFpEF)

• Describe the current management of HFrEF

• Present the evidence for ARNI in HFrEF

• Apply the clinical practice guideline for ARNI in HFrEF

 

Renal Protection in Patients with Diabetes and Advanced Nephropathy (Newly Updated 2025)

1. Describe advanced diabetic nephropathy and its consequences

2. Explain the rationale for the management of advanced nephropathy
   and the potential benefits

3. Describe how advanced nephropathy might be prevented

 

Blood Pressure Management in Patients with CKD

• Describe how to measure blood pressure to inform treatment decisions

• Describe healthy behaviours, for patients with CKD and hypertension, with a focus on sodium intake and physical activity

• Describe an approach and the rationale for the new lower blood pressure target in patients with CKD

• Contrast the strength of evidence for prescribing renin-angiotensin-system inhibitors (RASi) for people with hypertension and CKD with and without proteinuria, with and without diabetes

• Management of hyperkalemia to maintain RAASi therapy

 

SGLT2i for Cardiac Protection in Patients with Heart Failure

• Describe heart failure and its consequences

• Explain the rationale for the management of heart failure to include SGLT2i and the potential benefits

• Describe how and when to introduce SGLT2i for heart failure

 

FRENCH MODULES

​

Réduction du Risque Cardiovasculaire dans le Diabète (Inhibiteurs SGLT2, Agonistes des Récepteurs GLP-1, nsMRA chez les Patients atteints de Diabète et de Maladie Cardiovasculaire)

Objectifs du Programme:

À l’issue de ce programme, les participants seront en mesure de :

• Identifier les patients atteints de diabète et de maladie cardiovasculaire (MCV) qui pourraient bénéficier d’un inhibiteur SGLT2, d’un agoniste des récepteurs GLP-1, d’un nsMRA.

• Expliquer la justification clinique de ces traitements ainsi que leurs bénéfices potentiels pour la réduction du risque cardiovasculaire.

• Décrire les étapes pour initier, ajuster et surveiller ces thérapies afin d’optimiser la prise en charge des patients diabétiques.

 

Protection Rénale Chez Les Patients Atteints de Diabète et de Nephropathie Avancée

Objectifs d’apprentissage

• Décrire la néphropathie diabétique avancée et ses conséquences

• Expliquer les motifs de la prise en charge de la néphropathie avancée et les bienfaits potentiels

• Décrire la façon dont la néphropathie avancée peut être prévenue

 

Les Inhibiteurs SGLT2 pour la Protection Cardiaque chez les Patients Insuffisants Cardiaques

Objectifs du Programme :

• Décrire l'insuffisance cardiaque et ses conséquences.

• Expliquer la justification de la prise en charge de l'insuffisance cardiaque, y compris l'utilisation des inhibiteurs SGLT2 et leurs bénéfices potentiels.

• Décrire comment et quand introduire un inhibiteur SGLT2 dans le traitement de l'insuffisance cardiaque.

​

​

​